Lamotrigine

규격

84057-84-1CAS 번호

281-901-8EC 번호

6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamineIUPAC 명칭

C9H7Cl2N5화학식

256.09 g/mol분자량

lamotrigine; 84057-84-1; 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine; Lamictal; Lamictal Cd; Lamotrigina; Lamictal XR; Lamotriginum; BW 430C; 3,5-Diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine; BW-430C; Lamictal ODT; 1,2,4-Triazine-3,5-diamine, 6-(2,3-dichlorophenyl)-; 3,5-Diamino-6-(2,3-dichlorophenyl)-as-triazine; DTXSID2023195; BW430C; NSC-759171; SUBVENITE; GW 273293; U3H27498KS; CHEBI:6367; DTXCID203195; Lamotirigine; Lamotrigine ER; LAMOTRIGINE Kit; RefChem:5936; lamotrigine extended-release; Lamotrigine Extended Release; lamotrigine chewable dispersible; N03AX09; 281-901-8; 658-035-8; Lamotriginum [Latin]; Lamotrigina [Spanish]; Labileno; Lamitor; C9H7Cl2N5; MFCD00865333; LTG;BW430C; CHEMBL741; MLS000069685; s3024; NCGC00015605-06; Lamictin; SMR000058464; 6-(2,3-Dichloro-phenyl)-[1,2,4]triazine-3,5-diamine; (6M)-6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine; Lamictal (TN); CAS-84057-84-1; SR-01000000187; EINECS 281-901-8; UNII-U3H27498KS; Lamictal;; Lamotrigine CRS; HSDB 7526; EUR-1048; IYJ; Lamotrigine [USAN:USP:INN:BAN]; Opera_ID_12; Lamotrigine (Standard); Tocris-1611; Lamotrigine 100 microg/mL in Acetonitrile; LAMOTRIGINE [MI]; LAMOTRIGINE [INN]; LAMOTRIGINE [JAN]; Lopac-L-3791; LAMOTRIGINE [HSDB]; LAMOTRIGINE [USAN]; L 3791; LAMOTRIGINE [MART.]; Lopac0_000688; SCHEMBL35439; LAMOTRIGINE [USP-RS]; LAMOTRIGINE [WHO-DD]; MLS000759486; MLS001077325; MLS001423991; BIDD:GT0794; Lamotrigine (JAN/USP/INN); Lamotrigine, >=98%, powder; GTPL2622; orb1310392; orb3141187; Lamotrigine, 1mg/ml in Ethanol; Lamotrigine - Bio-X trade mark; SCHEMBL29360953; SCHEMBL29801510; HY-B0495R; LAMOTRIGINE [EP IMPURITY]; LAMOTRIGINE [ORANGE BOOK]; GLXC-07355; HMS2051C10; HMS2089M08; HMS2093P21; HMS2230L04; HMS3262I17; HMS3268G17; HMS3371O16; HMS3393C10; HMS3657A17; HMS3715H21; HMS3885M03; HMS5081I06; LAMOTRIGINE [EP MONOGRAPH]; LAMOTRIGINE [USP IMPURITY]; Pharmakon1600-01505610; LAMOTRIGINE [USP MONOGRAPH]; HY-B0495; Lamotrigine 1.0 mg/ml in Methanol; MSK10267; Tox21_110179; Tox21_500688; BDBM50031299; EBC-03614; HB0368; NSC746307; NSC759171; STK628377; AKOS005561147; Lamotrigine for system suitability CRS; Tox21_110179_1; 6-(2,2,4-triazine-3,5-diyldiamine; CCG-100856; DB00555; ID58057; KS-1074; Lamotrigine for peak identification CRS; LP00688; NC00106; NSC 746307; NSC 759171; NSC-746307; SDCCGSBI-0050666.P003; SMP2_000303; NCGC00015605-01; NCGC00015605-02; NCGC00015605-03; NCGC00015605-04; NCGC00015605-05; NCGC00015605-07; NCGC00015605-08; NCGC00015605-09; NCGC00015605-10; NCGC00015605-23; NCGC00015605-24; NCGC00015605-25; NCGC00022936-02; NCGC00022936-04; NCGC00022936-05; NCGC00261373-01; AC-10298; AC-32483; BL166799; SBI-0050666.P002; DB-014839; EU-0100688; L0241; NS00000354; SW197486-3; D00354; EN300-120680; W13018; AB00384359-16; AB00384359_17; AB00384359_18; F093440; Q410346; 3,5-diamino-(2,3-dichlorophenyl)-1,2,4-triazine; SR-01000000187-2; SR-01000000187-4; SR-01000000187-7; BRD-K93460210-001-22-9; BRD-K93460210-001-23-7; BRD-K93460210-071-01-6; SR-01000000187-10; 3,5-diamino-6-(2,3,-dichlorophenyl)-1,2,4-triazine; F2173-0540; Z1532338577; Lamotrigine Working Standard (Secondary Reference Standard); Lamotrigine, British Pharmacopoeia (BP) Reference Standard; Lamotrigine, European Pharmacopoeia (EP) Reference Standard; 1,2,4-TRIAZINE-3,5-DIAMINE, 6-(2,3-DICHLOROPHENYL); 6-(2,3-Dichloro-phenyl)-[1,2,4]triazine-3,5-diamine(lamotrigine); GI 267119X; 6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine; Lamotrigine, United States Pharmacopeia (USP) Reference Standard; Lamotrigine, Pharmaceutical Secondary Standard; Certified Reference Material; Lamotrigine for peak identification, European Pharmacopoeia (EP) Reference Standard; Lamotrigine for system suitability, European Pharmacopoeia (EP) Reference Standard동의어